Xarelto is a relatively new prescription blood thinner (also known as anticoagulant) which has had tremendous success in the US market since its initial debut.
The drug was first approved by the FDA in 2011 for reducing the risks of blood clots in patients undergoing knee or hip replacement surgeries.
Since its initial approval Xarelto has received the green light for many other uses including the treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE).
Alleged benefits along with heavy promotion have helped Xarelto to quickly become the leading blood thinner in its class in the US market.
In fact, the blockbuster drug has been prescribed more than 11 million times in America.
However, recent studies have linked the use of Xarelto to dangerous side effects including severe internal bleeding which can lead to injury or death.
About The New Study
Results from a new study published in the British Medical Journal suggest that the use of Xarelto may double the risk for gastrointestinal bleeding when compared to the generic version of Warfarin.
The study, which consisted of over 45,000 patients, aimed to determine the overall safety of rivaroxaban (the generic version of Xarelto) when compared with warfarin in terms of the risk of gastrointestinal bleeding as a side effect.
In the conclusions of the study researchers stated, “we cannot rule out a more than twofold higher risk of bleeding with rivaroxaban compared with Warfarin.”
Xarelto Lawsuits Being Filed By Injured Plaintiffs
Xarelto lawyer Stephen A. Sheller commented on the study saying, “This is one of several recently published studies which have investigated a link between Xarelto and severe internal bleeding side effects. The results of these studies have prompted individuals and families throughout the country to take legal action by filing claims against the manufacturers of the drug. We are currently helping many families by providing information and assistance in pursuing justice.”
Sheller.com is an online resource center which provides information and news about pending Xarelto litigation. For all media contacts and questions regarding Xarelto lawsuits please call us.